Get the Stockscreener App
5.24
0.57%
-0.03
After Hours:
5.32
0.08
+1.53%
Abcellera Biologics Inc stock is traded at $5.24, with a volume of 2.95M.
It is down -0.57% in the last 24 hours and up +5.86% over the past month.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
See More
Previous Close:
$5.27
Open:
$5.3
24h Volume:
2.95M
Relative Volume:
0.49
Market Cap:
$1.60B
Revenue:
$79.21M
Net Income/Loss:
$-143.96M
P/E Ratio:
-10.93
EPS:
-0.4796
Net Cash Flow:
$-189.60M
1W Performance:
-6.76%
1M Performance:
+5.86%
6M Performance:
+44.75%
1Y Performance:
+66.35%
1-Day Range:
$5.13
$5.41
1-Week Range:
$5.02
$5.94
52-Week Range:
$2.745
$6.79
Abcellera Biologics Inc Stock (ABCL) Company Profile
Name
Abcellera Biologics Inc
Sector
Industry
Phone
(604) 559-9005
Address
150 W 4TH AVENUE, VANCOUVER
Compare ABCL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
5.24 | 1.61B | 79.21M | -143.96M | -189.60M | -0.4796 |
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.95B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
893.52 | 55.90B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 38.64B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.87 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-07-25 | Resumed | Leerink Partners | Outperform |
| Aug-20-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-22-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-06-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-13-23 | Resumed | Piper Sandler | Overweight |
| Feb-28-23 | Initiated | Cowen | Outperform |
| Dec-15-22 | Initiated | Goldman | Buy |
| Nov-16-22 | Initiated | Truist | Buy |
| Dec-21-21 | Initiated | The Benchmark Company | Buy |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Jan-05-21 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-21 | Initiated | Berenberg | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Outperform |
| Jan-05-21 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | Stifel | Buy |
View All
Abcellera Biologics Inc Stock (ABCL) Latest News
Is AbCellera (ABCL) Using Boardroom Oncology Talent to Redefine Its Clinical Ambitions? - simplywall.st
AbCellera Biologics (ABCL) grants director 111,701 share options - Stock Titan
AbCellera (ABCL) director Stephen Quake awarded 111,701 share options - Stock Titan
AbCellera (ABCL) director receives 111,701 share options grant - Stock Titan
AbCellera (NASDAQ: ABCL) shareholders back directors, auditor and Say-on-Pay - Stock Titan
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? - MSN
AbCellera (ABCL) director Sandor Victor reports initial insider status on Form 3 - Stock Titan
Wall Street Analysts Think ABCELLERA BIOLG (ABCL) Could Surge 85.59%: Read This Before Placing a Bet - MSN
AbCellera: Q3 Hot Flashes Data Drop Aside, This Stock Is A Difficult Sell (NASDAQ:ABCL) - Seeking Alpha
Q3 2025 Abcellera Biologics Inc Earnings Call Transcript - GuruFocus
AbCellera Biologics Hits Day Low of $5.50 Amid Price Pressure - Markets Mojo
AbCellera Appoints Dr. Victor Sandor to its Board of Directors - BioSpace
A Look At AbCellera Biologics (ABCL) Valuation After ABCL635 Progress And Strong Q1 Results - Yahoo Finance
AbCellera’s Shift To Proprietary Drugs Puts ABCL635 And Governance In Focus - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
AbCellera appoints Victor Sandor to board of directors - Investing.com UK
AbCellera appoints Victor Sandor to board of directors By Investing.com - Investing.com South Africa
AbCellera Biologics bets on hot flash antibody as pipeline pivot gains steam - MSN
AbCellera Biologics Adds Victor Sandor to Board - TipRanks
AbCellera appoints Victor Sandor to its Board - TradingView
AbCellera (NASDAQ: ABCL) appoints oncology leader Dr. Victor Sandor as independent director - Stock Titan
ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill
Abcellera Biologics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Q1 2026 Abcellera Biologics Inc Earnings Call Transcript - GuruFocus
Abcellera Biologics Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam - TradingView
ABCL Stock Jumps As Earnings Beat And Drug Data Fuel Momentum - StocksToTrade
ABCL: Lead antibody for menopausal hot flashes advances to phase II, targeting a $6B market - TradingView
ABCL Technical Analysis | Trend, Signals & Chart Patterns | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill
AbCellera (NASDAQ: ABCL) CFO exercises 250,000 share options - Stock Titan
Is AbCellera (ABCL) Turning Upgraded Earnings Forecasts Into a Durable Clinical-Stage Business Model? - simplywall.st
AbCellera Biologics Hits Day High with 12.47% Surge in Stock Price - Markets Mojo
AbCellera Biologics Hits Day High with 7.68% Surge in Stock Price - Markets Mojo
AbCellera Biologics Hits New 52-Week High of $6.79, Up 84% - Markets Mojo
Abcellera Biologics stock hits 52-week high at 6.52 USD By Investing.com - Investing.com India
After golden cross, AbCellera Biologics Inc. (ABCL)'s technical outlook is bright - MSN
Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year? - MSN
Abcellera Biologics stock hits 52-week high at 6.52 USD - Investing.com
AbCellera Biologics (NASDAQ:ABCL) Is In A Good Position To Deliver On Growth Plans - Moomoo
After Golden Cross, AbCellera Biologics Inc. (ABCL)'s Technical Outlook is Bright - Yahoo Finance
ABCL - Finviz
ABCL Technical Analysis & Stock Price Forecast - Intellectia AI
Does AbCellera (ABCL) Have a Clear Path From ABCL635 Data to a Durable Business Model? - Yahoo Finance
AbCellera Biologics Inc. (ABCL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Truist raises AbCellera stock price target on clinical data promise By Investing.com - Investing.com Nigeria
Here’s Why AbCellera (ABCL) is Among the 10 Best Penny Stocks to Buy for Long Term - Insider Monkey
Truist raises AbCellera stock price target on clinical data promise - Investing.com UK
Abcellera Biologics Inc Stock (ABCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):